Anthony E. Maida III

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Irvine, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Anthony Maida
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Anthony E. Maida III

Form 4 holding DIRECTOR AND CMO - TRANS. MED., Director

Oncotelic Therapeutics, Inc.

Security class
Stock Options
Shares / value
600,000
Estimated value
Report date
03 Sep 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding DIRECTOR AND CMO - TRANS. MED., Director

Oncotelic Therapeutics, Inc.

Security class
Restricted stock Units
Shares / value
1,500
Estimated value
Report date
10 Jul 2026
Price
Ownership
Direct
Underlying class
Series A Preferred Stock
Underlying amount

Insider Reports Filed by Anthony E. Maida III

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .